NCT07208734Enrolling by invitation
Personalized Brain Stimulation for Cognitive Impairment in Older Adults
Development and Multicenter Validation of a Personalized Transcranial Alternating Current Stimulation Protocol for Cognitive Impairment in Older Adults
Source: ClinicalTrials.gov · Last updated 6 Oct 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study aims to develop and test new personalized treatments for older adults with cognitive impairment. Project 1: Create a personalized cognitive training program using computer algorithms to match training tasks to individual needs. About 300 participants will join a randomized trial at hospitals and community health centers. Project 2: Develop a personalized brain stimulation program (tACS) based on brain imaging and artificial intelligence. About 160 participants will be enrolled to test safety and effectiveness. Project 3: Build a framework for ethical data management by reviewing international practices and consulting experts. Together, these projects will provide evidence for safe, effective, and personalized care, while ensuring responsible use of research data.
- Status (registry)
- Enrolling by invitation
- Study type
- Interventional
- Enrollment
- 460 (estimated)
- First submitted
- 28 Sept 2025
- Start date
- 1 May 2024
- Primary completion date
- 1 Jun 2027
- Lead sponsor
- Xuanwu Hospital, Beijing
- Diseases
- Alzheimer disease
- NCT number
- NCT07208734
What you commit to
- Study type: Interventional
- Planned participants: 460
- From 1 May 2024 to the primary completion date, 1 Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Documented history of cerebrovascular stroke, with clear neurological deficits at onset and corresponding responsible lesions on neuroimaging;
- Presence of any cause of consciousness disorder;
- Current psychiatric disorders;
- History of alcohol dependence, drug addiction, traumatic brain injury, epilepsy, encephalitis, normal-pressure hydrocephalus, or other neurological disorders that may cause cognitive impairment;
- Systemic diseases that may contribute to mild cognitive impairment (e.g., hepatic or renal insufficiency, endocrine disorders, vitamin deficiencies);
Other
- Moderate to severe white matter lesions (Fazekas score 3-6);
- Severe aphasia or motor disability that prevents completion of neuropsychological assessments;
- Considered unsuitable for participation by the investigators.
Who the study is looking for
- Inpatients or outpatients aged 50-90 years;
- Patients diagnosed with amnestic mild cognitive impairment (aMCI) due to AD or mild dementia due to AD, based on the 2018 NIA-AA clinical diagnostic criteria established by the National Institute on Aging and the Alzheimer's Association;
- Neuropsychological assessment showing MMSE scores between 18 and 26, and a CDR score of 0.5 or 1;
- Able to communicate fluently in Chinese (non-illiterate);
- For those currently receiving cholinesterase inhibitor therapy (e.g., donepezil or rivastigmine), the treatment dose must be stable, defined as a fixed dosage administered continuously for at least six weeks, with no adjustment of the medication regimen during the study period;
- Provision of written informed consent.
Age in the registry: 50 years to 90 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Xuanwu Hospital, Capital Medical University, Beijing, Beijing 100053 Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.